Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclobenzaprine is a centrally acting skeletal muscle relaxant used as an adjunct to rest and physical therapy for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. It is structurally related to tricyclic antidepressants and acts primarily within the central nervous system at the brainstem level. The precise mechanism of action is not fully understood, but it is believed to reduce tonic somatic motor activity influencing both alpha and gamma motor neurons. Cyclobenzaprine exhibits antagonistic activity at serotonin (5-HT2) receptors in the spinal cord, inhibits norepinephrine reuptake, and has anticholinergic effects. It does not act directly on skeletal muscle or neuromuscular junctions[1][2][4][5][6]. The drug is indicated for short-term use (typically 2–3 weeks) in adults and adolescents aged 15 years or older[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclobenzaprine.